Key points
- NeuroStrip has secured UK MHRA registration
- Registration enables commercial supply in England, Scotland, and Wales
- Early trials with leading institutions underway
- Feedback from trials to inform UK market entry strategy
Full summary
Control Bionics Limited announced that its wearable surface electromyography device, NeuroStrip, has received registration from the UK Medicines and Healthcare products Regulatory Agency (MHRA). This registration clears the primary regulatory hurdle for commercial supply in Great Britain, confirming the company's status as a registered medical device manufacturer. The UK offers a well-established and well-funded rehabilitation and research sector, alongside elite sports markets, all of which represent potential applications for NeuroStrip. Three pilot programs demonstrating the device's clinical and performance value are already underway, with several additional customer trials due to start in September 2026. Initial customers include Dr. Tom Maden-Wilkinson (University of Lancaster and University of Sheffield) and the University of Nottingham and British Olympics.